These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 18572454)

  • 1. Genetics of warfarin response.
    Kulkarni UP; Karnad DR; Gogtay NJ
    N Engl J Med; 2008 Jun; 358(25):2742-3; author reply 2743-4. PubMed ID: 18572454
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenomics--ready for prime time?
    Shurin SB; Nabel EG
    N Engl J Med; 2008 Mar; 358(10):1061-3. PubMed ID: 18322288
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetics of warfarin response.
    Mannucci PM; Spreafico M; Peyvandi F
    N Engl J Med; 2008 Jun; 358(25):2743; author reply 2743-4. PubMed ID: 18572453
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetics of warfarin response.
    Neville KA; Wicklund BM; Kearns GL
    N Engl J Med; 2008 Jun; 358(25):2742. PubMed ID: 18572452
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetic analysis to prevent warfarin complications.
    Lippi G; Salvagno GL; Guidi GC
    CMAJ; 2007 Aug; 177(4):377. PubMed ID: 17698833
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic testing for warfarin dosing? Not yet ready for prime time.
    Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
    Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacogenetic-based dosing of warfarin.
    Med Lett Drugs Ther; 2008 May; 50(1286):39-40. PubMed ID: 18487958
    [No Abstract]   [Full Text] [Related]  

  • 8. Dosing anticoagulant therapy with coumarin drugs: is genotyping clinically useful? No.
    Mannucci PM; Spreafico M; Peyvandi F
    J Thromb Haemost; 2008 Sep; 6(9):1450-2. PubMed ID: 18627441
    [No Abstract]   [Full Text] [Related]  

  • 9. Multiple gene polymorphisms and warfarin sensitivity.
    Shikata E; Ieiri I; Ishiguro S; Takane H; Ohgi S; Otsubo K
    Eur J Clin Pharmacol; 2006 Oct; 62(10):881-3. PubMed ID: 16821005
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic help for a blood-thinner balancing act? There's little evidence yet that a genetic test improves the safety of warfarin.
    Harv Heart Lett; 2007 Dec; 18(4):1-2. PubMed ID: 18219801
    [No Abstract]   [Full Text] [Related]  

  • 11. The pharmacogenomics of warfarin (Coumadin) administration.
    Ruano G; Bower B
    Conn Med; 2006 Apr; 70(4):251-2. PubMed ID: 16768072
    [No Abstract]   [Full Text] [Related]  

  • 12. Application of a pharmacogenetic-based warfarin dosing algorithm derived from British patients to predict dose in Swedish patients.
    Hatch E; Wynne H; Avery P; Wadelius M; Kamali F
    J Thromb Haemost; 2008 Jun; 6(6):1038-40. PubMed ID: 18419746
    [No Abstract]   [Full Text] [Related]  

  • 13. Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin.
    Siguret V; Pautas E; Gouin-Thibault I
    Vitam Horm; 2008; 78():247-64. PubMed ID: 18374198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen.
    Sconce EA; Kamali F
    Eur J Haematol; 2006 Dec; 77(6):457-62. PubMed ID: 17042764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes.
    Fukuda T; Tanabe T; Ohno M; Tougou K; Fujio Y; Azuma J; Yamamoto I; Takeda A
    Clin Pharmacol Ther; 2006 Nov; 80(5):553-4. PubMed ID: 17112813
    [No Abstract]   [Full Text] [Related]  

  • 16. [Genetic and bioenvironmental factors associated with warfarin response in Colombian patients].
    Isaza C; Beltrán L; Henao J; Porras G; Pinzón A; Vallejos A; Machado J
    Biomedica; 2010; 30(3):410-20. PubMed ID: 21713343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A vitamin K epoxide reductase complex subunit-1 (VKORC1) mutation in a patient with vitamin K antagonist resistance.
    Bodin L; Horellou MH; Flaujac C; Loriot MA; Samama MM
    J Thromb Haemost; 2005 Jul; 3(7):1533-5. PubMed ID: 15978113
    [No Abstract]   [Full Text] [Related]  

  • 18. Refining the use of warfarin through genetic testing.
    Lee SC
    Int Angiol; 2008 Aug; 27(4):271-3. PubMed ID: 18677287
    [No Abstract]   [Full Text] [Related]  

  • 19. Genetic influences on the response to warfarin.
    Kamali F
    Curr Opin Hematol; 2006 Sep; 13(5):357-61. PubMed ID: 16888441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.
    Loebstein R; Vecsler M; Kurnik D; Austerweil N; Gak E; Halkin H; Almog S
    Clin Pharmacol Ther; 2005 May; 77(5):365-72. PubMed ID: 15900282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.